Free Trial
NASDAQ:ISRG

Intuitive Surgical (ISRG) Stock Price, News & Analysis

$444.53
+0.77 (+0.17%)
(As of 07/8/2024 ET)
Today's Range
$441.56
$445.96
50-Day Range
$370.62
$445.11
52-Week Range
$254.85
$448.10
Volume
1.28 million shs
Average Volume
1.32 million shs
Market Capitalization
$157.67 billion
P/E Ratio
80.24
Dividend Yield
N/A
Price Target
$404.79

Intuitive Surgical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.74 Rating Score
Upside/​Downside
8.9% Downside
$404.79 Price Target
Short Interest
Healthy
1.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
1.09mentions of Intuitive Surgical in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$6.93 M Sold Last Quarter
Proj. Earnings Growth
20.00%
From $4.80 to $5.76 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.58 out of 5 stars

Medical Sector

73rd out of 876 stocks

Surgical Appliances & Supplies Industry

4th out of 18 stocks

ISRG stock logo

About Intuitive Surgical Stock (NASDAQ:ISRG)

Intuitive Surgical, Inc. is a leading medical technology company specializing in robotic-assisted surgical systems. Founded in 1995, the company's mission is to improve patient outcomes through the use of innovative technology and minimally invasive surgical techniques. Headquartered in Sunnyvale, California, Intuitive Surgical operates globally, serving healthcare professionals and patients in over 60 countries.

Intuitive Surgical's flagship product is the da Vinci Surgical System, a robotic platform that enables surgeons to perform complex procedures with enhanced precision, control, and visualization. The system consists of robotic arms controlled by the surgeon, along with a high-definition 3D camera and specialized surgical instruments. This advanced technology allows for smaller incisions, reduced scarring, shorter recovery times, and improved clinical outcomes.

The company's target market primarily includes hospitals and surgical centers specializing in urology, gynecology, general, and thoracic surgery. Intuitive Surgical has established itself as a leader in these fields and has a strong customer base, including prestigious medical institutions and renowned surgeons. The company's dedication to innovation and patient care has garnered numerous accolades, including recognition as one of Fortune's "World's Most Admired Companies" in the healthcare industry.

Intuitive Surgical is led by an experienced management team committed to driving the company's growth and maintaining its position as a leader in surgical robotics. Dr. Gary Guthart is the Chief Executive Officer and has been instrumental in guiding the company's strategic direction. Under his leadership, Intuitive Surgical has expanded its product portfolio, entered new markets, and achieved remarkable financial success.

Intuitive Surgical has consistently delivered strong financial performance over the past few years. The company's revenue has experienced steady growth, reaching $6.22 billion in the latest fiscal year. With a strong focus on operational efficiency, Intuitive Surgical has maintained healthy profit margins, enabling it to invest in research and development and expand its market reach.

The company has a solid balance sheet with manageable debt levels. This provides stability and financial flexibility for future investments and acquisitions. Intuitive Surgical's financial performance is notably impressive compared to industry benchmarks, reflecting its strong market position and competitive advantage.

Intuitive Surgical commands a premium compared to its industry peers. The company's price-to-earnings ratio, a commonly used valuation measure, is higher than average due to its strong growth prospects and dominant market position. Investors have recognized the company's innovation and potential for long-term success, contributing to its higher valuation.

Intuitive Surgical has exhibited remarkable stock performance in recent years. The company's share price has experienced significant growth, reflecting investor confidence in its business model and growth potential. Notably, the stock has outperformed broader market indices and many of its industry peers.

Intuitive Surgical operates in the rapidly evolving field of surgical robotics, which is transforming the healthcare landscape. The industry is characterized by intense competition, with major players including Medtronic, Johnson & Johnson, and Stryker Corporation. These companies continually invest in research and development to enhance their robotic surgical systems and expand their market presence.

Regulatory and political factors also play a significant role in the industry. Government agencies, such as the U.S. Food and Drug Administration (FDA), regulate the approval and safety of robotic surgical systems. Changes in regulations or introducing new policies can impact the industry landscape and market access for companies like Intuitive Surgical.

Despite the competitive landscape, Intuitive Surgical maintains a solid competitive advantage. The company's pioneering da Vinci Surgical System has established a dominant position in the market, with a large installed base worldwide. This gives Intuitive Surgical a significant edge in terms of customer loyalty and brand recognition. Additionally, the company's focus on continuous innovation and product development enables it to stay ahead of the competition.

Acquisitions and strategic partnerships offer growth opportunities for Intuitive Surgical. The company has a strong balance sheet enabling it to pursue strategic acquisitions that complement its existing product portfolio or provide access to new markets. Collaborating with other medical technology companies or research institutions can also fuel innovation and open doors to novel surgical solutions.

Like any company operating in the healthcare industry, Intuitive Surgical faces various risks and challenges. One significant risk is the potential for changes in healthcare policies and reimbursement rates. Government policies can directly impact the adoption and utilization of robotic surgical systems, which could affect the demand for Intuitive Surgical's products.

Another challenge is emerging new technologies or surgical techniques that may compete with or disrupt the robotic-assisted surgery market. Technological advancements in artificial intelligence and virtual reality could offer alternative solutions to traditional surgical procedures. Intuitive Surgical must stay at the forefront of innovation and adapt its offerings to remain competitive.

Additionally, the company faces the risk of product recalls or safety concerns. As robotic surgical systems become more complex, ensuring their reliability and patient safety becomes paramount. Intuitive Surgical must continue to invest in quality control measures, regulatory compliance, and ongoing training for surgeons to mitigate these risks.

ISRG Stock Price History

ISRG Stock News Headlines

Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.
3 Hidden AI Gems That Could Outshine the Giants
Intuitive Surgical (NASDAQ:ISRG) PT Raised to $425.00
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.
2 Top Healthcare Stocks to Buy in June
3 AI and Robotics Stocks Leading Innovation
The 3 Best Medical Device Stocks to Buy in June 2024
3 Healthcare Stocks to Buy Now: June 2024
See More Headlines
Receive ISRG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intuitive Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/18/2024
Today
7/08/2024
Next Earnings (Confirmed)
7/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ISRG
CUSIP
46120E60
Employees
13,676
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$404.79
High Stock Price Target
$500.00
Low Stock Price Target
$314.00
Potential Upside/Downside
-8.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.74
Research Coverage
19 Analysts

Profitability

Net Income
$1.80 billion
Pretax Margin
28.36%

Debt

Sales & Book Value

Annual Sales
$7.12 billion
Cash Flow
$5.43 per share
Book Value
$38.03 per share

Miscellaneous

Free Float
351,862,000
Market Cap
$157.67 billion
Optionable
Optionable
Beta
1.39

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

ISRG Stock Analysis - Frequently Asked Questions

How have ISRG shares performed this year?

Intuitive Surgical's stock was trading at $337.36 at the start of the year. Since then, ISRG shares have increased by 31.8% and is now trading at $444.53.
View the best growth stocks for 2024 here
.

How were Intuitive Surgical's earnings last quarter?

Intuitive Surgical, Inc. (NASDAQ:ISRG) posted its quarterly earnings data on Thursday, April, 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The business's revenue was up 11.5% compared to the same quarter last year.
Read the conference call transcript
.

When did Intuitive Surgical's stock split?

Intuitive Surgical shares split on Tuesday, October 5th 2021. The 3-1 split was announced on Thursday, August 5th 2021. The newly issued shares were distributed to shareholders after the closing bell on Monday, October 4th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What is Gary S. Guthart's approval rating as Intuitive Surgical's CEO?

431 employees have rated Intuitive Surgical Chief Executive Officer Gary S. Guthart on Glassdoor.com. Gary S. Guthart has an approval rating of 99% among the company's employees. This puts Gary S. Guthart in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Does Intuitive Surgical have any subsidiaries?

Intuitive Surgical subsidiaries include Orpheus Medical, NeoGuide Systems, Computer Motion, Intuitive Surgical AB, Intuitive Surgical ApS, Intuitive Surgical Australia Proprietary Limited, Intuitive Surgical Brasil Importacao E Comercio De Equipamentos Cirurgicos Ltda, and more.

Who are Intuitive Surgical's major shareholders?

Top institutional shareholders of Intuitive Surgical include Woodstock Corp (0.03%), DNB Asset Management AS (0.02%), Hudson Valley Investment Advisors Inc. ADV (0.02%) and Douglas Lane & Associates LLC (0.01%). Insiders that own company stock include David J Rosa, Marshall Mohr, Alan J Levy, Mark J Rubash, Amal M Johnson, Gary S Guthart, Robert Desantis, Amy L Ladd, Myriam Curet, Mark Brosius, Fredrik Widman, Craig H Barratt, Jamie Samath and Keith R Leonard.
View institutional ownership trends
.

How do I buy shares of Intuitive Surgical?

Shares of ISRG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Intuitive Surgical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intuitive Surgical investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Salesforce (CRM), PayPal (PYPL) and Walt Disney (DIS).

This page (NASDAQ:ISRG) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners